INTRODUCTION
were then disrupted using a high pressure homogenizer (Emulsiflex-C5, Avestin).
Following centrifugation (17000 rpm, 4°C, 40 min) the clarified supernatant was passed through a 10 ml DE-52 column to remove DNA. The flow through was applied to a 2 ml Ni-NTA (Qiagen) column, washed with 20 ml of 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 5 mM imidazole and 0.5 mM TCEP and eluted by raising the imidazole concentration to 250 mM. The eluted peak was loaded onto a S75 16/60 prep grade (GE/Amersham) gel filtration column in 10 mM HEPES, pH 7.5 500 mM NaCl, 5% glycerol and 0.5 mM TCEP. The essentially pure DHRS10 containing peak was concentrated (Vivaspin 20, Vivascience, MWCO 15K) to a final concentration of 12 mg/ml. After flash freezing in liquid nitrogen the protein was stored at -80°C for further analysis by crystallization or substrate screening. The mass of the purified product was verified by LC/MS on an Agilent LC/MSD TOF system (Agilent, UK).
Crystallization and structure determination: Crystals were grown by the sitting drop vapour diffusion method in 24 well sitting drop Cryschem plates (Hampton Research) at 20°C. 2 µl of the concentrated protein were mixed with 2 µl of 0.2 M magnesium acetate, 0.1 M sodium cacodylate, pH 6.5 and 20% (v/v) 2-methyl-2,4-pentanediol (MPD). The crystals were flash cooled in liquid nitrogen and X-ray diffraction data were collected at 100 K, at beamline 17-ID, Advanced Photon Source (APS), Argonne, Illinois, USA at a wavelength of 0.9794 Å. Data were indexed, integrated and scaled using the HKL2000 suite [11] . Phases were obtained by molecular replacement using the program PHASER [12] . Since a single highest homology model did not give a molecular replacement solution, a superimposed ensemble of eleven homologous structures (sequence identity between 30-38%) was used as a molecular replacement model. Refinement was initiated using strict NCS constraints in CNS [13] . However, in later stages it became apparent that the four tetramers in the asymmetric unit have A2B2 symmetry, the main difference crystallographic R-factor of 0.181 and R free of 0.229. The coordinates and structure factors were deposited at the protein data bank (PDB) with the code 1YDE.
Ligand docking: Two consecutive ligand docking procedures were performed according to the methodology described by Totrov and Abagyan [16, 17] and implemented in the program ICM v.3.4-1: one to position the NAD molecule into the cofactor binding pocket and a second one to dock the estradiol molecule into the active site of DHRS10. In both cases, grid maps representing different properties of the enzyme were computed. During the docking, either one of the torsional angles of the ligand was randomly changed or a pseudo-brownian move was performed. Each random change was followed by 100 steps of local conjugate-gradient minimization. The new conformation was accepted or rejected according to metropolis criteria using a temperature of 600 K. The length (number of Monte Carlo steps) of the docking run as well as the length of local minimization was determined automatically by an adaptive algorithm, depending on the size and number of flexible torsions in the ligand. The lowest energy conformation satisfying the absence of clashes after docking NAD + was incorporated into the structure file of DHRS10 and this was in turn used as receptor for the docking of estradiol. In this second docking, a positional restraint was imposed on the O17 atom of estradiol and the Tyr 154-OH, based on the catalytic mechanism of SDR enzymes [18, 19] .
Substrate screening and kinetic analysis of purified recombinant human DHRS10: A
compound library comprising 50 different steroids (androgen, estrogen, progestin, glucocorticoid hormones, bile acids and oxysterols; obtained from Sigma and Steraloids) with hydroxy/keto functions at position 3, 7, 11, 17, 20 and 21 were screened against purified human DHRS10 using a fluorescence-based assay on cofactor fluorescence change in a Spectramax M2 microplate reader (Molecular Devices). Steroids were dissolved in DMSO with stock solutions ranging from 5-20 mM, and were further diluted 1: 1000 in the assay mixture (oxidation: 50 mM Tris-HCl pH 8.5, 100 mM NaCl, 200 µM NAD + or NADP + , 50 -100 µg/ml enzyme, reduction: 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 µM NADH or NADPH). Excitation was set to 340 nm, emission was at 460 nm, and the assay was conducted in 96 well plates (Costar). Initial hits from this Copyright 2006 Biochemical Society screen were verified by analysis of product formation using radioactively labeled steroids with an HPLC system coupled to online radioactivity detection. Kinetic analysis was carried out in 96 well plates as described above, or in single, 10 mm pathlength quartz cuvettes, by varying steroid substrate (200 nM -100 µM) and cofactor (0.1 µM -10 mM) concentrations. Initial velocities were converted into product formation using freshly prepared nucleotide cofactor solutions as standards, and data obtained were fitted Radioactively labelled nucleotides were purchased from Amersham Biosciences (Uppsala, Sweden). Detection was done by autoradiography using BioMax XAR films (Kodak Industrie, Chalon-sur-Saône, Cedex, France).
RESULTS

Expression, purification and activity of human DHRS10: Full length DHRS10 was
expressed and purified in a two step chromatographic procedure yielding about 20 mg per litre of culture. The purified protein was judged homogeneous by SDS-PAGE and mass spectrometry (data not shown), and was found suitable for subsequent use in substrate screening, kinetic and crystallographic studies. A fluorescent assay was used to carry out substrate screening against a collection of different steroids. Purified DHRS10 enzyme turned over NAD + to NADH in the presence of estradiol, testosterone or 5-androstene-3β, 17β-diol. Michaelis-Menten kinetics were observed for estradiol and 5-androstene-3β, 17β-diol; with K m values of 5.6 ± 1.7 and 13.6 ± 1.6 µM, and V max values of 2.5 ± 1.0 and 9.1 ± 1.6 nmol NADH min -1 mg -1 for estradiol and 5-androstene-3β, 17β-diol respectively. However non saturable kinetics were found for testosterone ( Figure 2 , Table   2 ). No conversion was observed in the presence of NADP(H) or with β-OH-butyryl CoA which is a bona fide substrate for other 17β-HSDs such as 17β-HSD4 and 17β-HSD10 (Table 2) .
DHRS10 activity in intact cells: In order to verify steroid conversion by DHRS10 in intact cells and to investigate the direction of the DHRS10 reaction in vivo, Hek293T
Biochemical Journal Immediate Publication. Published on 27 Oct 2006 as manuscript BJ20061319 cells were transfected with an expression plasmid encoding DHRS10 and exposed to 20 nM radiolabeled estradiol. The transfected cells efficiently oxidised estradiol to estrone as revealed by HPLC analysis of the supernatant (Figure 2 ). This conversion rate is significantly faster in comparison to that of mock transfected cells (pcDNA3 vector only). Therefore, intact cells expressing DHRS10 can indeed oxidize steroids at physiological hormone concentrations.
Crystal Structure of DHRS10:
Following extensive crystallisation trials the purified protein yielded well diffracting crystals suitable for crystallographic analysis. The crystal structure of DHRS10 was solved by molecular replacement to a resolution of 2.4 Å, and a summary of data processing and refinement statistics is compiled in Table 1 . The asymmetric unit contains sixteen DHRS10 monomers arranged as four tetramers with 222-point group symmetry. Each monomer comprises two distinct regions ( Figure 3 ):
The first region is a Rossmann-fold built up of a central β-sheet core consisting of 7 parallel β-strands (βA-βG) sandwiched between two arrays of parallel helices (αB-αG).
This region has a characteristic nucleotide cofactor (NAD(H) or NADP(H)) binding
motif T-G-X3-G-X-G located near its N-terminus. Residue Asp 40 is present at the Cterminal end of the second β-strand (βB). In SDR structures the presence of an acidic residue at this location indicates a NAD(H) versus NAD(P) selectivity, since the carboxylate group is in a favourable location to interact with the 2′ and 3′ OH groups of the adenosine ribose of NAD. Accordingly, this residue prohibits NADP(H) binding by repelling the negative charge on the 2′ phosphate and thus confers NAD(H) specificity to DHRS10 [20]. Kinetic analysis (cf above) confirmed NAD(H) as the cofactor for the DHRS10 reaction. Also within this region is a very short α-helix (αEF) inserted between αE and βF and encompassing residues 142-147. A second region contains two additional alpha-helical elements αFG1 (residues 189-197) and αFG2 (residues 201-212) that are inserted between βF and αG. As with all SDRs whose structures have been determined so far, this second region is more variable and is responsible for substrate binding.
In the apostructure determined, a broad active site cleft lies between the two regions indicating two distinct transcription or splicing sites in brain and placenta, whereas in liver only one mRNA species is observed (Figure 7 ).
DISCUSSION
In this study we have identified DHRS10 as a cytosolic SDR enzyme with 17β-HSD activity on steroid substrates. Out of the human tissues investigated the highest levels of DHRS10 expression were observed in the brain, liver and placenta.
The DHRS10 gene was initially cloned in an attempt to define retinoid metabolizing enzymes, however, this function was excluded after heterologous expression [9] . To our knowledge, no further functional studies are available on this human gene or any mammalian ortholog. To investigate the structural and functional features of the enzyme, we determined the crystal structure and correlate these results to functional analyses. To this end, experimental structure determination appears to be essential to derive at functional conclusions. We performed homology modelling of human DHRS10 using the two closest available structures as templates, namely Rv2002 gene product from Mycobacterium tuberculosis (PDB code 1NFQ) and TT0321 from Thermus thermophilus HB8 (PDB code 2D1Y), both with 38% sequence identity. Although the predicted folding was very similar to the experimental structure, and homology modeling could be performed in a satisfactory manner for most of the molecule, an important active site segment comprising ~14 residues was not correctly predicted due to high sequence variation. Thus, a docking analysis to suggest possible substrates for de-orphanisation of DHRS10 could not be carried out due to the lack of reliable templates for this critical portion of the structure. Structure prediction for a segment with such size to the level required for de-orphanisation via docking methods is therefore still beyond the reach of present technology.
In common with the majority of 17β-HSDs the crystal structure displays the typical characteristics of the short-chain dehydrogenase/reductase family with a largely Together with the expression observed in tissues such as liver, brain and placenta, the proven in vivo and in vitro function of DHRS10 as oxidative 17β-hydroxy dehydrogenase, suggest possible roles for DHRS10 in the local regulation of active steroid hormones levels [1, 2] . DHRS10 would therefore be responsible for steroid inactivation similar to 17β-HSD2. However, as shown in this work the tissue distribution of DHRS10 is distinct to that reported for type 2 [31, 32] and because of that a tissuespecific function is postulated. This is in analogy to other 17β-or 11β-HSD enzymes that constitute critical determinants of steroid hormone physiology [1] . It appears in several situations essential that steroid ligands are excluded from their receptors, as is the case with glucocorticoids and the mineralocorticoid receptor.
Our in vitro data indicate that DHRS10 is involved in the local inactivation of 5androstene-3β, 17β-diol and of estradiol, and taken together with the initial expression data obtained in this study, suggest possible functional roles mainly in the placenta and the CNS. The activity and expression in the CNS thus adds DHRS10 isozyme to the complexity of estrogen and DHEA metabolizing steroid dehydrogenases observed in a study conducted by Steckelbroeck et al [33] , noting multiple 17β-HSDs involved in human brain tissues. The weak estrogenic steroid 5-androstene-3β, 17β-diol is an important metabolic intermediate in the peripheral sex steroid synthesis starting from DHEA. 5-androstene-3β, 17β-diol is secreted by the adrenal gland, and like the sex steroids display important functions in the brain such as hippocampal neurogenesis and neural survival [34] . Estrogens have an extensive range of effects on the brain [35] . These include effects on brain development [36] , centrally regulated effects on reproduction, mood [37] , cognition [38] , protection from neurotoxins/neurodegeneration or injury [39, 40] , neuron plasticity [41] , transcription of neuropeptides [42] and regulative effects on the enzymes that affect the synthesis and turnover of classical neurotransmitters e.g. serotonin [43] and dopamine [44] .
It is clear that the cytosolic localisation of DHRS10 could allow control by access by limiting exogenously and endogenously produced active estrogen (estradiol) from reaching to estrogen ERα/β receptors located in the nucleus. Interestingly surface membrane associated estrogen receptors, whose existence have also been recently demonstrated [45, 46] , would allow bypass of such control.
Taken together, we have provided a structural and functional characterization of a yet poorly annotated mammalian gene product. Further studies concerning temporal and spatial expression patterns, animal studies, as well as a search for other possible substrate activities will be mandatory for the additional annotation of this SDR member. Jornvall, H., Persson, B., Krook, M., Atrian, S., Gonzalez-Duarte, R., Jeffery, J. and Ghosh, D. (1995) Short-chain dehydrogenases/reductases (SDR).
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